<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Despite availability of efficient treatment regimens for early stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, treatment regimens for late stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> are generally not effective and thus need improvement </plain></SENT>
<SENT sid="1" pm="."><plain>Oncolytic virotherapy using replication-competent <z:e sem="disease" ids="C0042214" disease_type="Disease or Syndrome" abbrv="">vaccinia</z:e> virus (VACV) strains is a promising new strategy for therapy of a variety of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Oncolytic efficacy of replication-competent <z:e sem="disease" ids="C0042214" disease_type="Disease or Syndrome" abbrv="">vaccinia</z:e> virus GLV-1h68 was analyzed in both, cell cultures and subcutaneous xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In this study we demonstrated for the first time that the replication-competent recombinant VACV GLV-1h68 efficiently infected, replicated in, and subsequently lysed various human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> lines (Colo 205, HCT-15, HCT-116, HT-29, and SW-620) derived from patients at <z:hpo ids='HP_0000001'>all</z:hpo> four stages of disease </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> in athymic <z:mp ids='MP_0003815'>nude</z:mp> mice, a single injection of intravenously administered GLV-1h68 significantly inhibited <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> of two different human colorectal cell line <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (Duke's type A-stage HCT-116 and Duke's type C-stage SW-620), significantly improving survival compared to untreated mice </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of the <z:mp ids='MP_0001799'>viral</z:mp> marker gene ruc-gfp allowed for real-time analysis of the <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> in cell cultures and in mice </plain></SENT>
<SENT sid="6" pm="."><plain>GLV-1h68 treatment was well-tolerated in <z:hpo ids='HP_0000001'>all</z:hpo> animals and <z:mp ids='MP_0001799'>viral</z:mp> replication was confined to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>GLV-1h68 treatment elicited a significant up-regulation of murine immune-related antigens like IFN-γ, IP-10, <z:chebi fb="17" ids="50099">MCP</z:chebi>-1, <z:chebi fb="17" ids="50099">MCP</z:chebi>-3, <z:chebi fb="17" ids="50099">MCP</z:chebi>-5, RANTES and TNF-γ and a greater infiltration of macrophages and NK cells in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> as compared to untreated controls </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity observed against <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells in these studies was a result of direct <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0333516" disease_type="Neoplastic Process" abbrv="">oncolysis</z:e> by GLV-1h68 and <z:mp ids='MP_0001845'>inflammation</z:mp>-mediated innate immune responses </plain></SENT>
<SENT sid="9" pm="."><plain>The therapeutic effects occurred in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> regardless of the stage of disease from which the cells were derived </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, the recombinant <z:e sem="disease" ids="C0042214" disease_type="Disease or Syndrome" abbrv="">vaccinia</z:e> virus GLV-1h68 has the potential to treat <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> independently of the stage of progression </plain></SENT>
</text></document>